换肤

主营介绍

  • 主营业务:

    特色原料药、制剂的生产和销售以及为国际制药企业提供定制生产、配套研发的服务;环保型活性染料、染料中间体以及颜料中间体的生产和销售。

  • 产品类型:

    抗生素类、降糖类、心血管类、染料、染颜料中间体

  • 产品名称:

    抗生素培南系列(主要为培南中间体4-AA产品 、 KETO 、 MAP及美罗培南原料药等) 、 抗生素克林霉素系列(盐酸克林霉素 、 克林霉素棕榈酸酯 、 克林霉素磷酸酯等) 、 盐酸万古霉素 、 氟苯尼考 、 甲砜霉素 、 伏格列波糖 、 瑞格列 、 达比加群酯的中间体OA/MD 、 活性艳蓝KN-R型产品,包括KN-R(HG) 、 KN-R(SR) 、 KN-R(SP) 、 氨基油 、 溴氨酸 、 间位酯 、 DCB

  • 经营范围:

    药品的生产(范围详见《中华人民共和国药品生产许可证》),化工原料及产品的生产,经营进出口业务。(依法须经批准的项目,经相关部门批准后方可开展经营活动。)。

运营业务数据

最新公告日期:2022-04-23 
业务名称 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
医药库存量(千克) 25.11万 19.65万 - - -
染料库存量(吨) 1547.61 1249.45 - - -
医药行业库存量(千克) - - 41.58万 33.31万 30.47万
染料行业库存量(吨) - - 1868.83 1815.01 1375.73

主营构成分析

{"2022-06-30":{"YYSR":{"1":[["\u533b\u836f","102698.70"],["\u67d3\u6599","43394.38"],["\u5176\u4ed6","688.08"]],"2":[["\u539f\u6599\u836f\u53ca\u533b\u836f\u4e2d\u95f4\u4f53","92063.71"],["\u67d3\u6599\u53ca\u67d3\u989c\u6599\u4e2d\u95f4\u4f53","43394.38"],["\u5408\u540c\u5b9a\u5236\u4e1a\u52a1","10483.21"],["\u5176\u4ed6","688.08"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",151.78]],"3":[["\u56fd\u5916","80236.62"],["\u56fd\u5185","66544.54"]]},"YYCB":{"1":[["\u533b\u836f","70623.59"],["\u67d3\u6599","30564.36"],["\u5176\u4ed6","700.72"]],"2":[["\u539f\u6599\u836f\u53ca\u533b\u836f\u4e2d\u95f4\u4f53","65860.13"],["\u67d3\u6599\u53ca\u67d3\u989c\u6599\u4e2d\u95f4\u4f53","30564.36"],["\u5408\u540c\u5b9a\u5236\u4e1a\u52a1","4630.62"],["\u5176\u4ed6","700.72"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",132.85]],"3":[["\u56fd\u5916","50993.28"],["\u56fd\u5185","50895.39"]]},"LRBL":{"1":[["\u533b\u836f","71.45"],["\u67d3\u6599","28.58"],["\u5176\u4ed6","-0.03"]],"2":[["\u539f\u6599\u836f\u53ca\u533b\u836f\u4e2d\u95f4\u4f53","58.37"],["\u67d3\u6599\u53ca\u67d3\u989c\u6599\u4e2d\u95f4\u4f53","28.58"],["\u5408\u540c\u5b9a\u5236\u4e1a\u52a1","13.04"],["\u5176\u4ed6","-0.03"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0.04]],"3":[["\u56fd\u5916","65.14"],["\u56fd\u5185","34.86"]]}},"2021-12-31":{"YYSR":{"1":[["\u533b\u836f","148387.11"],["\u67d3\u6599","98860.27"],["\u5176\u4ed6","1235.46"]],"2":[["\u539f\u6599\u836f","95155.50"],["\u67d3\u6599","66612.05"],["\u533b\u836f\u4e2d\u95f4\u4f53","52776.81"],["\u67d3\u6599\u4e2d\u95f4\u4f53","32248.22"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",1690.25]],"3":[["\u56fd\u5916","137063.13"],["\u56fd\u5185","111419.72"]]},"YYCB":{"1":[["\u533b\u836f","101283.78"],["\u67d3\u6599","53665.09"],["\u5176\u4ed6","990.30"]],"2":[["\u539f\u6599\u836f","69064.49"],["\u67d3\u6599","33849.66"],["\u533b\u836f\u4e2d\u95f4\u4f53","31882.35"],["\u67d3\u6599\u4e2d\u95f4\u4f53","19815.42"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",1327.23]],"3":[["\u56fd\u5916","81040.11"],["\u56fd\u5185","74899.05"]]},"LRBL":{"1":[["\u533b\u836f","50.90"],["\u67d3\u6599","48.84"],["\u5176\u4ed6","0.26"]],"2":[["\u539f\u6599\u836f","28.19"],["\u67d3\u6599","35.40"],["\u533b\u836f\u4e2d\u95f4\u4f53","22.58"],["\u67d3\u6599\u4e2d\u95f4\u4f53","13.43"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0.39]],"3":[["\u56fd\u5916","60.54"],["\u56fd\u5185","39.46"]]}},"2021-06-30":{"YYSR":{"1":[["\u533b\u836f","67610.03"],["\u67d3\u6599","50707.67"],["\u5176\u4ed6","569.04"]],"2":[["\u539f\u6599\u836f","41496.93"],["\u67d3\u6599","30782.89"],["\u533b\u836f\u4e2d\u95f4\u4f53","25867.15"],["\u67d3\u6599\u4e2d\u95f4\u4f53","19924.78"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",815]],"3":[["\u56fd\u5916","69581.34"],["\u56fd\u5185","49305.41"]]},"YYCB":{"1":[["\u533b\u836f","47136.02"],["\u67d3\u6599","25105.37"],["\u5176\u4ed6","471.89"]],"2":[["\u539f\u6599\u836f","31263.20"],["\u67d3\u6599","14842.35"],["\u533b\u836f\u4e2d\u95f4\u4f53","15641.88"],["\u67d3\u6599\u4e2d\u95f4\u4f53","10263.03"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",702.83]],"3":[["\u56fd\u5916","41797.98"],["\u56fd\u5185","30915.30"]]},"LRBL":{"1":[["\u533b\u836f","44.34"],["\u67d3\u6599","55.45"],["\u5176\u4ed6","0.21"]],"2":[["\u539f\u6599\u836f","22.16"],["\u67d3\u6599","34.52"],["\u533b\u836f\u4e2d\u95f4\u4f53","22.15"],["\u67d3\u6599\u4e2d\u95f4\u4f53","20.92"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0.24]],"3":[["\u56fd\u5916","60.17"],["\u56fd\u5185","39.83"]]}}}
{"YYSR":{"chartWrap1":[{"name":"\u533b\u836f","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[102698.7,148387.11,67610.03],"columnData":[69.97,59.72,56.87],"unit":["10.27\u4ebf","14.84\u4ebf","6.76\u4ebf"]},{"name":"\u67d3\u6599","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[43394.38,98860.27,50707.67],"columnData":[29.56,39.79,42.65],"unit":["4.34\u4ebf","9.89\u4ebf","5.07\u4ebf"]},{"name":"\u5176\u4ed6","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[688.08,1235.46,569.04],"columnData":[0.47,0.5,0.48],"unit":["688.08\u4e07","1235.46\u4e07","569.04\u4e07"]}],"chartWrap2":[{"name":"\u539f\u6599\u836f\u53ca\u533b\u836f\u4e2d\u95f4\u4f53","timeData":["2022-06-30"],"lineData":[92063.71],"columnData":[62.72],"unit":["9.21\u4ebf"]},{"name":"\u67d3\u6599\u53ca\u67d3\u989c\u6599\u4e2d\u95f4\u4f53","timeData":["2022-06-30"],"lineData":[43394.38],"columnData":[29.56],"unit":["4.34\u4ebf"]},{"name":"\u5408\u540c\u5b9a\u5236\u4e1a\u52a1","timeData":["2022-06-30"],"lineData":[10483.21],"columnData":[7.14],"unit":["1.05\u4ebf"]},{"name":"\u5176\u4ed6","timeData":["2022-06-30"],"lineData":[688.08],"columnData":[0.47],"unit":["688.08\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[151.78,1690.25,815],"columnData":[0.1,0.68,0.69],"unit":["151.78\u4e07","1690.25\u4e07","815.00\u4e07"]},{"name":"\u539f\u6599\u836f","timeData":["2021-12-31","2021-06-30"],"lineData":[95155.5,41496.93],"columnData":[38.29,34.9],"unit":["9.52\u4ebf","4.15\u4ebf"]},{"name":"\u67d3\u6599","timeData":["2021-12-31","2021-06-30"],"lineData":[66612.05,30782.89],"columnData":[26.81,25.89],"unit":["6.66\u4ebf","3.08\u4ebf"]},{"name":"\u533b\u836f\u4e2d\u95f4\u4f53","timeData":["2021-12-31","2021-06-30"],"lineData":[52776.81,25867.15],"columnData":[21.24,21.76],"unit":["5.28\u4ebf","2.59\u4ebf"]},{"name":"\u67d3\u6599\u4e2d\u95f4\u4f53","timeData":["2021-12-31","2021-06-30"],"lineData":[32248.22,19924.78],"columnData":[12.98,16.76],"unit":["3.22\u4ebf","1.99\u4ebf"]}],"chartWrap3":[{"name":"\u56fd\u5916","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[80236.62,137063.13,69581.34],"columnData":[54.66,55.16,58.53],"unit":["8.02\u4ebf","13.71\u4ebf","6.96\u4ebf"]},{"name":"\u56fd\u5185","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[66544.54,111419.72,49305.41],"columnData":[45.34,44.84,41.47],"unit":["6.65\u4ebf","11.14\u4ebf","4.93\u4ebf"]}]},"YYCB":{"chartWrap1":[{"name":"\u533b\u836f","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[70623.59,101283.78,47136.02],"columnData":[69.31,64.95,64.82],"unit":["7.06\u4ebf","10.13\u4ebf","4.71\u4ebf"]},{"name":"\u67d3\u6599","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[30564.36,53665.09,25105.37],"columnData":[30,34.41,34.53],"unit":["3.06\u4ebf","5.37\u4ebf","2.51\u4ebf"]},{"name":"\u5176\u4ed6","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[700.72,990.3,471.89],"columnData":[0.69,0.64,0.65],"unit":["700.72\u4e07","990.30\u4e07","471.89\u4e07"]}],"chartWrap2":[{"name":"\u539f\u6599\u836f\u53ca\u533b\u836f\u4e2d\u95f4\u4f53","timeData":["2022-06-30"],"lineData":[65860.13],"columnData":[64.64],"unit":["6.59\u4ebf"]},{"name":"\u67d3\u6599\u53ca\u67d3\u989c\u6599\u4e2d\u95f4\u4f53","timeData":["2022-06-30"],"lineData":[30564.36],"columnData":[30],"unit":["3.06\u4ebf"]},{"name":"\u5408\u540c\u5b9a\u5236\u4e1a\u52a1","timeData":["2022-06-30"],"lineData":[4630.62],"columnData":[4.54],"unit":["4630.62\u4e07"]},{"name":"\u5176\u4ed6","timeData":["2022-06-30"],"lineData":[700.72],"columnData":[0.69],"unit":["700.72\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[132.85,1327.23,702.83],"columnData":[0.13,0.86,0.97],"unit":["132.85\u4e07","1327.23\u4e07","702.83\u4e07"]},{"name":"\u539f\u6599\u836f","timeData":["2021-12-31","2021-06-30"],"lineData":[69064.49,31263.2],"columnData":[44.29,43],"unit":["6.91\u4ebf","3.13\u4ebf"]},{"name":"\u67d3\u6599","timeData":["2021-12-31","2021-06-30"],"lineData":[33849.66,14842.35],"columnData":[21.71,20.41],"unit":["3.38\u4ebf","1.48\u4ebf"]},{"name":"\u533b\u836f\u4e2d\u95f4\u4f53","timeData":["2021-12-31","2021-06-30"],"lineData":[31882.35,15641.88],"columnData":[20.45,21.51],"unit":["3.19\u4ebf","1.56\u4ebf"]},{"name":"\u67d3\u6599\u4e2d\u95f4\u4f53","timeData":["2021-12-31","2021-06-30"],"lineData":[19815.42,10263.03],"columnData":[12.71,14.11],"unit":["1.98\u4ebf","1.03\u4ebf"]}],"chartWrap3":[{"name":"\u56fd\u5916","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[50993.28,81040.11,41797.98],"columnData":[50.05,51.97,57.48],"unit":["5.10\u4ebf","8.10\u4ebf","4.18\u4ebf"]},{"name":"\u56fd\u5185","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[50895.39,74899.05,30915.3],"columnData":[49.95,48.03,42.52],"unit":["5.09\u4ebf","7.49\u4ebf","3.09\u4ebf"]}]},"LRBL":{"chartWrap1":[{"name":"\u533b\u836f","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[71.45,50.9,44.34],"columnData":[71.45,50.9,44.34],"unit":["71.45\u4e07","50.90\u4e07","44.34\u4e07"]},{"name":"\u67d3\u6599","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[28.58,48.84,55.45],"columnData":[28.58,48.84,55.45],"unit":["28.58\u4e07","48.84\u4e07","55.45\u4e07"]},{"name":"\u5176\u4ed6","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[-0.03,0.26,0.21],"columnData":[-0.03,0.26,0.21],"unit":["-300","2600.00","2100.00"]}],"chartWrap2":[{"name":"\u539f\u6599\u836f\u53ca\u533b\u836f\u4e2d\u95f4\u4f53","timeData":["2022-06-30"],"lineData":[58.37],"columnData":[58.37],"unit":["58.37\u4e07"]},{"name":"\u67d3\u6599\u53ca\u67d3\u989c\u6599\u4e2d\u95f4\u4f53","timeData":["2022-06-30"],"lineData":[28.58],"columnData":[28.58],"unit":["28.58\u4e07"]},{"name":"\u5408\u540c\u5b9a\u5236\u4e1a\u52a1","timeData":["2022-06-30"],"lineData":[13.04],"columnData":[13.04],"unit":["13.04\u4e07"]},{"name":"\u5176\u4ed6","timeData":["2022-06-30"],"lineData":[-0.03],"columnData":[-0.03],"unit":["-300"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[0.04,0.39,0.24],"columnData":[0.04,0.39,0.24],"unit":["400.00","3900.00","2400.00"]},{"name":"\u539f\u6599\u836f","timeData":["2021-12-31","2021-06-30"],"lineData":[28.19,22.16],"columnData":[28.19,22.16],"unit":["28.19\u4e07","22.16\u4e07"]},{"name":"\u67d3\u6599","timeData":["2021-12-31","2021-06-30"],"lineData":[35.4,34.52],"columnData":[35.4,34.52],"unit":["35.40\u4e07","34.52\u4e07"]},{"name":"\u533b\u836f\u4e2d\u95f4\u4f53","timeData":["2021-12-31","2021-06-30"],"lineData":[22.58,22.15],"columnData":[22.58,22.15],"unit":["22.58\u4e07","22.15\u4e07"]},{"name":"\u67d3\u6599\u4e2d\u95f4\u4f53","timeData":["2021-12-31","2021-06-30"],"lineData":[13.43,20.92],"columnData":[13.43,20.92],"unit":["13.43\u4e07","20.92\u4e07"]}],"chartWrap3":[{"name":"\u56fd\u5916","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[65.14,60.54,60.17],"columnData":[65.14,60.54,60.17],"unit":["65.14\u4e07","60.54\u4e07","60.17\u4e07"]},{"name":"\u56fd\u5185","timeData":["2022-06-30","2021-12-31","2021-06-30"],"lineData":[34.86,39.46,39.83],"columnData":[34.86,39.46,39.83],"unit":["34.86\u4e07","39.46\u4e07","39.83\u4e07"]}]}}

营业收入 X

单位(%) 单位(万元)
注:通常在中报、年报时披露 
业务名称 营业收入(元) 收入比例 营业成本(元) 成本比例 利润比例 毛利率
按行业 医药 10.27亿 69.97% 7.06亿 69.31% 71.45% 31.23%
染料 4.34亿 29.56% 3.06亿 30.00% 28.58% 29.57%
其他 688.08万 0.47% 700.72万 0.69% -0.03% -1.84%
按产品 原料药及医药中间体 9.21亿 62.72% 6.59亿 64.64% 58.37% 28.46%
染料及染颜料中间体 4.34亿 29.56% 3.06亿 30.00% 28.58% 29.57%
合同定制业务 1.05亿 7.14% 4630.62万 4.54% 13.04% 55.83%
其他 688.08万 0.47% 700.72万 0.69% -0.03% -1.84%
制剂 151.78万 0.10% 132.85万 0.13% 0.04% 12.47%
按地区 国外 8.02亿 54.66% 5.10亿 50.05% 65.14% 36.45%
国内 6.65亿 45.34% 5.09亿 49.95% 34.86% 23.52%

主要客户及供应商

您对此栏目的评价: 有用 没用 提建议
前5大客户:共销售了4.89亿元,占营业收入的19.69%
">
  • 客户1
  • 客户2
  • 客户3
  • 客户4
  • 客户5
  • 其他
客户名称 销售额(元) 占比
客户1
1.43亿 5.76%
客户2
1.32亿 5.33%
客户3
7206.14万 2.90%
客户4
7104.08万 2.86%
客户5
7048.03万 2.84%
前5大供应商:共采购了2.28亿元,占总采购额的14.58%
">
  • 供应商1
  • 供应商2
  • 供应商3
  • 供应商4
  • 供应商5
  • 其他
供应商名称 采购额(元) 占比
供应商1
7188.25万 4.59%
供应商2
4494.33万 2.87%
供应商3
3933.54万 2.51%
供应商4
3684.82万 2.35%
供应商5
3543.34万 2.25%
前5大客户:共销售了5.69亿元,占营业收入的23.02%
">
  • 客户1
  • 客户2
  • 客户3
  • 客户4
  • 客户5
  • 其他
客户名称 销售额(元) 占比
客户1
2.02亿 8.18%
客户2
1.58亿 6.41%
客户3
7948.61万 3.22%
客户4
6857.06万 2.77%
客户5
6028.96万 2.44%
前5大供应商:共采购了2.15亿元,占总采购额的17.43%
">
  • 供应商1
  • 供应商2
  • 供应商3
  • 供应商4
  • 供应商5
  • 其他
供应商名称 采购额(元) 占比
供应商1
9742.86万 7.90%
供应商2
3561.46万 2.89%
供应商3
2814.09万 2.28%
供应商4
2761.50万 2.24%
供应商5
2611.92万 2.12%
前5大客户:共销售了6.49亿元,占营业收入的22.06%
">
  • 客户1
  • 客户2
  • 客户3
  • 客户4
  • 客户5
  • 其他
客户名称 销售额(元) 占比
客户1
2.12亿 7.21%
客户2
1.49亿 5.08%
客户3
1.06亿 3.59%
客户4
9365.76万 3.18%
客户5
8828.61万 3.00%
前5大供应商:共采购了3.28亿元,占总采购额的20.83%
">
  • 供应商1
  • 供应商2
  • 供应商3
  • 供应商4
  • 供应商5
  • 其他
供应商名称 采购额(元) 占比
供应商1
1.45亿 9.17%
供应商2
5666.04万 3.59%
供应商3
5285.68万 3.35%
供应商4
3842.01万 2.44%
供应商5
3590.26万 2.28%
前5大客户:共销售了5.06亿元,占营业收入的18.62%
">
  • 客户1
  • 客户2
  • 客户3
  • 客户4
  • 客户5
  • 其他
客户名称 销售额(元) 占比
客户1
1.38亿 5.09%
客户2
1.06亿 3.89%
客户3
9404.08万 3.46%
客户4
8946.50万 3.29%
客户5
7851.21万 2.89%
前5大供应商:共采购了3.82亿元,占总采购额的22.27%
">
  • 供应商1
  • 供应商2
  • 供应商3
  • 供应商4
  • 供应商5
  • 其他
供应商名称 采购额(元) 占比
供应商1
1.47亿 8.58%
供应商2
6758.48万 3.94%
供应商3
6582.36万 3.84%
供应商4
5814.89万 3.39%
供应商5
4323.54万 2.52%
前5大客户:共销售了4.72亿元,占营业收入的20.46%
">
  • 客户1
  • 客户2
  • 客户3
  • 客户4
  • 客户5
  • 其他
客户名称 销售额(元) 占比
客户1
1.17亿 5.06%
客户2
1.16亿 5.02%
客户3
9210.73万 3.99%
客户4
7808.76万 3.38%
客户5
6959.27万 3.01%
前5大供应商:共采购了3.72亿元,占总采购额的26.24%
">
  • 供应商1
  • 供应商2
  • 供应商3
  • 供应商4
  • 供应商5
  • 其他
供应商名称 采购额(元) 占比
供应商1
1.32亿 9.29%
供应商2
8594.57万 6.06%
供应商3
7862.64万 5.55%
供应商4
3981.98万 2.81%
供应商5
3581.50万 2.53%

董事会经营评述

  一、报告期内公司从事的主要业务
  公司是一家涵盖医药、染料全产业链的综合性医化企业,根据中国证监会颁发的《上市公司行业分类指引》,公司所处行业为医药制造业(C27)。医药板块业务涉及特色原料药及医药中间体、仿制药的研发和商业化生产销售,并为全球知名制药企业提供定制研发及生产服务(CMO/CDMO)。染料板块业务涉及环保型活性染料及染颜料中间体的研发、生产及销售。
  报告期内,公司所从事的主要业务、经营模式、所属行业发展情况等均未发生重大变化。
  1、报告期内经营情况
  报告期内,公司营业收入14.68亿元,同比增长23.46%,归属母公司净利润1.72亿元,同比增长183.71%。... 查看全部▼

  一、报告期内公司从事的主要业务
  公司是一家涵盖医药、染料全产业链的综合性医化企业,根据中国证监会颁发的《上市公司行业分类指引》,公司所处行业为医药制造业(C27)。医药板块业务涉及特色原料药及医药中间体、仿制药的研发和商业化生产销售,并为全球知名制药企业提供定制研发及生产服务(CMO/CDMO)。染料板块业务涉及环保型活性染料及染颜料中间体的研发、生产及销售。
  报告期内,公司所从事的主要业务、经营模式、所属行业发展情况等均未发生重大变化。
  1、报告期内经营情况
  报告期内,公司营业收入14.68亿元,同比增长23.46%,归属母公司净利润1.72亿元,同比增长183.71%。其中医药业务营业收入10.27亿元,同比增长51.90%,毛利3.21亿元,同比增长56.66%,公司业务构成发生较大变化,医药业务收入和利润贡献超七成,抵消染料行情低迷影响,为业绩增长提供强劲动力。
  2、报告期内重点推进工作:
  特色原料药及中间体业务:上半年公司原料药总产量高于去年同期,产业链前向一体化扩产显效。培南系列产能释放、销售旺盛,收入较上年同期同比翻番,毛利率持续回升,配合重要客户完成培南系列产品欧盟、美国市场注册申报;克林霉素系列、降糖系列、联苯双脂等走出疫情影响,实现较好增长;氟苯尼考收入同比增长,但因市场竞争激烈,毛利率偏低,目前正在工艺二次开发和产能建设储备。优势产品切入一致性评价合作,最近一轮集采已有客户中标,将带动公司相关产品销售增长;自有原料药品种管线布局新治疗领域,免疫类、肝胆类、精神类等潜力项目进展顺利,处于验证生产或试生产阶段,未来有望成为新拳头优势产品。
  CMO/CDMO业务:报告期内,CMO/CDMO业务实现收入1.05亿元,部分客户合作产品面临专利悬崖影响需求,已与该客户新增其他专利期产品合作,今明两年将逐步放量填补影响;川南多功能中试车间去年开始投入使用,CMO/CDMO产能规模、验证效率、综合服务能力实现质的提升,计划新投建一幢多功能中试车间,不断提升服务能力和产能。现有商业化合作14项,其中专利期项目2项,上半年新落地合作5项,进入小试对接的储备项目8项,其中临床期项目2项,明后年有望陆续实现收入。客户结构方面,存量国外客户合作产品数量增加,新增国内外其他客户,合作范围也向临床期项目拓展。
  制剂业务:依托优势原料药延伸下游制剂,打造“中间体+原料药+制剂”一体化优势品种,通过制剂放大收入和盈利。上半年伏格列波糖片、瑞格列奈片完成BE试验,一致性评价资料已递交CDE审核中。
  研发方面:梳理研发体系内部职能分工,上海研究院发挥桥头堡作用主要负责新产品立项、验证、小试等前端研发工作,同时负责CMO/CDMO新项目导入对接工作,台州研究院负责中试及商业化后端研发工作。未来持续引进化学合成、合成生物学,生物发酵、酶生物工程等方面高端实用型人才,充实研发团队,完善特色平台建设。上半年研发投入7,208.98万元,开展小试、中试、技改等各类研究38项,其中原料药10项,制剂3项,医药中间体17项。新递交专利申请3件,均为发明专利。新获得专利授权3件,均为发明专利。
  销售BD:深化销售体系改革,推进大客户战略,组建大客户事业部及CDMO事业部,积极快速响应客户需求,深度参与全球医药产业链协作。国际大客户方面增加业务黏性,充分利用合格供应商资格扩大合作规模及项目。国内国外客户并重,加强优势产品与国内头部药企合作,积极参与集采合作,最近一轮集采已有客户中标,将带动公司相关产品销售增长;与华益泰康、鑫开元分别签订战略合作,通过合作伙伴拓宽新业务BD渠道,已有3个新项目、新合作验证对接中。
  项目建设:规划各厂区职能分工,设医药中间体厂区、特色原料药厂区、制剂厂区三大平台。医药中间体产区项目投产后,培南前向中间体一体化扩产,产量大幅提升,产能持续平稳爬坡;特色原料药厂区完成培南原料药扩产、KETO车间和氟化车间改造升级,无菌原料药、A8等新产能建设完成工程设备安装,进入验证生产阶段,多功能中试车间投入使用,计划新投建一幢中试车间;制剂厂区免疫类项目完成车间改造,无菌粉针剂车间已完成设备安装,正在验证批生产,后续将根据进度启动注册报批;多剂型车间正在进行设备安装调试。“中间体+原料药+制剂”一体化产业平台逐步完善。湖北生产基地已完成入园评审等相关工作。公司近三年持续大规模资本性投入扩建生产线,随着配套产业链扩产及新项目投建已陆续步入尾声,产能利用率、资产使用效率迈入上升通道。
  染料业务:染料业务实现营业收入4.34亿元,在染料行业低迷的大环境下积极管理库存,以销定产,维持市场占有率。内部做好管理提升,工艺优化升级,改造车间回收利用副产物,新增溴乙烷产品并实现销售,变废为宝,增加经济效益和环保效益。拓展颜料和新材料领域合作,新开发颜料中间体,中试样品已获客户认可。

  二、核心竞争力分析
公司核心竞争力在报告期内无重大变化。

  三、公司面临的风险和应对措施
1、行业政策风险
医药行业是受到政府政策影响较大的行业之一,医药行业产业政策以及国家、地方性法律法规的变化,将直接影响医药行业的景气程度。随着国家医疗卫生体制改革的不断推进与深化,医药政策措施陆续出台,对医药行业带来了较大的改变和冲击。两票制、医保控费、集中采购、限制适应症、辅助用药目录、重点监控目录、药品审评制度、GMP飞行检查等相关政策出台和实施将深刻影响医药产业的各个领域,加强药品质量控制及药品控费将成为常态,药品销售面临较大的压力。公司管理层将时刻关注行业政策变化,积极采取应对措施以控制和降低生产经营风险。
2、汇率波动风险
公司国外市场销售收入占比较高,中美贸易摩擦以及国际经济形势的不稳定性带来的贸易障碍以及汇率波动,均会对公司销售收入和盈利能力带来一定影响。未来公司将采取针对性措施积极应对国际市场变化,努力稳固国际市场地位并积极开拓新的经济增长点,以保持公司业绩的稳步增长。
3、原材料价格波动风险
公司部分原材料在过去几年中有一定幅度的价格波动,该部分原材料价格的稳定性在一定程度上影响公司盈利水平的稳定性。公司通过不断强化原料采购的风险防控力度,合理控制库存水平,优化产品结构,技术改进提高收率等措施避免或减少原料价格波动风险。
4、环保和安全生产风险
公司在研发和生产过程中会产生废气、废水、废渣或其他污染物,如果处理方式不当,可能会对周围环境产生不利影响。公司自设立以来一直高度重视环境保护和安全生产工作,建立了一系列管理制度并有效执行,未发生重大安全生产事故和环保事故。但是,随着公司业务规模的逐步扩大,环保及安全生产方面的压力也在增大,可能会存在因设备故障、人为操作不当、自然灾害等不可抗力事件导致的安全环保方面事故的风险。公司一直注重环境保护和安全生产,近年来不断加大环保设施投入,提升管理水平,确保安全生产,做好环境保护。
5、人才缺乏的风险
随着公司规模的扩张和业务的拓展,公司在战略执行和推进中,可能存在管理人才和专业人才储备与公司发展需求不能很好匹配的风险。公司将外部引进和内部培养相结合,加强人才培养的力度,搭建人才发展平台,根据公司实际业务发展需要,引进相应高层次人才。 收起▲